Q2 EPS Estimates for Elevance Health Lowered by Analyst

Elevance Health, Inc. (NYSE:ELV) – Stock analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for Elevance Health in a research note issued to investors on Thursday, January 30th. Zacks Research analyst K. Dey now expects that the company will post earnings per share of $9.85 for the quarter, down from their previous forecast of $10.35. The consensus estimate for Elevance Health’s current full-year earnings is $34.07 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $5.31 EPS, FY2025 earnings at $34.16 EPS, Q1 2026 earnings at $12.30 EPS, Q2 2026 earnings at $11.67 EPS, Q3 2026 earnings at $10.23 EPS, Q4 2026 earnings at $6.10 EPS and FY2026 earnings at $40.30 EPS.

A number of other brokerages have also recently weighed in on ELV. Morgan Stanley reduced their target price on Elevance Health from $643.00 to $551.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. UBS Group dropped their target price on Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a research report on Friday, October 18th. Royal Bank of Canada dropped their target price on Elevance Health from $585.00 to $478.00 and set an “outperform” rating on the stock in a research report on Friday, October 18th. Wells Fargo & Company lowered their price objective on Elevance Health from $483.00 to $478.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Truist Financial decreased their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $517.03.

Elevance Health Price Performance

Shares of Elevance Health stock opened at $405.54 on Monday. Elevance Health has a twelve month low of $362.21 and a twelve month high of $567.26. The stock has a market capitalization of $94.05 billion, a P/E ratio of 15.84, a PEG ratio of 1.19 and a beta of 0.83. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The business’s fifty day moving average price is $386.50 and its 200 day moving average price is $456.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a dividend of $1.71 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. This represents a $6.84 annualized dividend and a yield of 1.69%. Elevance Health’s payout ratio is presently 25.46%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ELV. Centaurus Financial Inc. increased its holdings in shares of Elevance Health by 66.9% in the second quarter. Centaurus Financial Inc. now owns 918 shares of the company’s stock valued at $498,000 after buying an additional 368 shares in the last quarter. Czech National Bank raised its stake in Elevance Health by 6.7% during the 3rd quarter. Czech National Bank now owns 47,237 shares of the company’s stock valued at $24,563,000 after purchasing an additional 2,947 shares during the period. Handelsbanken Fonder AB raised its stake in Elevance Health by 4.1% during the 3rd quarter. Handelsbanken Fonder AB now owns 75,320 shares of the company’s stock valued at $39,166,000 after purchasing an additional 2,987 shares during the period. GAMMA Investing LLC raised its stake in Elevance Health by 19.3% during the 3rd quarter. GAMMA Investing LLC now owns 3,098 shares of the company’s stock valued at $1,611,000 after purchasing an additional 502 shares during the period. Finally, Chemistry Wealth Management LLC raised its stake in Elevance Health by 4.0% during the 3rd quarter. Chemistry Wealth Management LLC now owns 6,793 shares of the company’s stock valued at $3,533,000 after purchasing an additional 261 shares during the period. Institutional investors own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.